According to a July 31 announcement, LucyRx has signed a definitive agreement to bring CerpassRx under its umbrella. The transaction is subject to regulatory approvals and customary closing conditions and is expected to close in Q3 2025.
CerpassRx is a leading, full-service, pharmacy benefit manager (PBM) based in the Dallas-Fort Worth, Texas area. Its services include prescription optimization, flexible formulary designs, personalized member support and mail and specialty pharmacy programs. CerpassRx is a division of Nomi Health, a direct healthcare company.
LucyRx is a PBM known for simplifying and improving access to prescription care. Partnering with more than 60,000 pharmacies, LucyRx serves more than 1,200 clients nationwide.
There will be no changes to service, support or operations as a result of this agreement. As part of this agreement, Nomi Health and LucyRx will continue working together to support their shared clients and build on current partnership efforts to reduce pharmacy costs for both employers and their members. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the first PBM deal announcement of 2025. There were no PBM deals announced in 2024. The low deal activity in the PBM sector stems from high market concentration, where the top four PBMs (OptumRx, CVS Health, Express Scripts and Prime Therapeutics) hold 67% of the market share, creating antitrust barriers to further consolidation. Intense FTC scrutiny and state regulations targeting anti-competitive practices, such as spread pricing, have also made buyers hesitant.
